Skip to main content
SpringerLink
Log in

Xefo® Rapid: A novel effective tool for pain treatment

Xefo® Rapid: Ein neues, effektives Mittel zur Schmerzbehandlung

  • Review
  • Published:
European Surgery Aims and scope Submit manuscript

Zusammenfassung

GRUNDLAGEN: Zur perioperativen Schmerztherapie wird ein multimodales Konzept mit Einbeziehung von nichtsteroidalen antiinflammatorischen Medikamenten (NSAIDs) empfohlen. Lornoxicam ist ein NSAID der Oxicam-Klasse. METHODIK: Übersicht zu Lornoxicam. ERGEBNISSE: Lornoxicam kann oral und parenteral appliziert werden, zeichnet sich durch einen raschen Wirkungsbeginn, eine kurze Halbwertszeit und geringe Nebenwirkungen aus. Pharmakokinetische und pharmakologische Aspekte werden in dem Artikel dargestellt. SCHLUSSFOLGERUNGEN: Lornoxicam (Xefo® und Xefo® Rapid) stellt eine wertvolle Alternative zu Opiaten in der postoperativen Schmerztherapie dar.

Summary

BACKGROUND: A multimodal approach to perioperative pain, including nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended. Lornoxicam is an NSAID of the oxicam class. METHODS: Review on Lornoxicam. RESULTS: Lornoxicam is available in oral (standard and quick-release) and parenteral formulations. It is characterised by a relatively quick onset of action and a short elimination half-life. Several studies have shown the efficacy of lornoxicam in the perioperative setting. Lornoxicam was as effective as opioid analgesics in reducing postoperative pain and showed a better tolerability profile. Due to its opioid-sparing effect, lornoxicam might also be used in combination with opioid analgesics. In addition, it was comparable to other NSAIDs in treating musculoskeletal pain, like osteoarthritis and back pain. Safety and tolerability of lornoxicam show advantages when compared to other NSAIDs, with gastrointestinal disturbances being the most common adverse reactions. The report rate of adverse events was very low in the available studies, which could be a positive effect of the short half-life. CONCLUSIONS: Lornoxicam (Xefo® and Xefo® Rapid) is a valuable tool for relieving postoperative pain as an alternative to or adjuvant for opioid analgesics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Carr DB, Goudas LC (1999) Acute pain. Lancet 353: 2051–2058

    Article  PubMed  CAS  Google Scholar 

  • Papper EM, Brodie BB, Rovenstine EA (1952) Postoperative pain; its use in the comparative evaluation of analgesics. Surgery 32: 107–109

    PubMed  CAS  Google Scholar 

  • Moote C (1992) Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain. Drugs 44 (Suppl 5): 14–29; discussion 29–30

    PubMed  Google Scholar 

  • (1995) Practice guidelines for acute pain management in the perioperative setting. A report by the American Society of Anesthesiologists Task Force on Pain Management, Acute Pain Section. Anesthesiology 82: 1071–1081

  • Dahl V, Raeder JC (2000) Non-opioid postoperative analgesia. Acta Anaesthesiol Scand 44: 1191–1203

    Article  PubMed  CAS  Google Scholar 

  • Vane JR, Botting RM (1995) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44: 1–10

    Article  PubMed  CAS  Google Scholar 

  • Caporali R, Montecucco C (2005) Cardiovascular effects of coxibs. Lupus 14: 785–788

    Article  PubMed  CAS  Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528, 1522–1528

    Google Scholar 

  • Fenner H (1987) Comparative biochemical pharmacology of the oxicams. Scand J Rheumatol Suppl 65: 97–101

    PubMed  CAS  Google Scholar 

  • Olkkola KT, Brunetto AV, Mattila MJ (1994) Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 26: 107–120

    Article  PubMed  CAS  Google Scholar 

  • Skjodt NM, Davies NM (1998) Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet 34: 421–428

    Article  PubMed  CAS  Google Scholar 

  • Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D (1990) Pharmacokinetics of lornoxicam in man. Postgrad Med J 66 (Suppl 4): S22–S27

    PubMed  CAS  Google Scholar 

  • Suwa T, Urano H, Shinohara Y, Kokatsu J (1993) Simultaneous high-performance liquid chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J Chromatogr 617: 105–110

    PubMed  CAS  Google Scholar 

  • Balfour JA, Fitton A, Barradell LB (1996) Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51: 639–657

    PubMed  CAS  Google Scholar 

  • Bonnabry P, Leemann T, Dayer P (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 49: 305–308

    Article  PubMed  CAS  Google Scholar 

  • Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H (2005) Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol 59: 14–17

    Article  PubMed  CAS  Google Scholar 

  • Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H (2005) Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33: 749–753

    Article  PubMed  CAS  Google Scholar 

  • Dittrich P, Radhofer-Welte S, Magometschnigg D, Kukovetz WR, Mayerhofer S, Ferber HP (1990) The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drugs Exp Clin Res 16: 57–62

    PubMed  CAS  Google Scholar 

  • Ravic M, Johnston A, Turner P (1990) Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgrad Med J 66 (Suppl 4): S30–S34

    PubMed  Google Scholar 

  • Ravic M, Salas-Herrera I, Johnston A, Turner P, Foley K, Rosenow DE (1993) A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad Med J 69: 865–866

    PubMed  CAS  Google Scholar 

  • Kohl C, Steinkellner M (2000) Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 28: 161–168

    PubMed  CAS  Google Scholar 

  • Ravic M, Johnston A, Turner P, Ferber HP (1990) A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 9: 413–414

    PubMed  CAS  Google Scholar 

  • Hitoglou-Makedou A, Lawson M, Turner P, Ferber HP (1989) Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis. Postgrad Med J 65: 821–823

    PubMed  CAS  Google Scholar 

  • Kukovetz WR, Appleqvist T (1996) A randomized, threeway cross-over, open-label phase I study to compare the bioavailibility and pharmacokinetic profile of Lornoxicam applied as oral quick-release formulation (fil-coated tablet), as oral standard formulation (film-coated tablet) and as i.m. injection in healthy volunteers CT.101. Nycomed Pharma AG, Denmark (Data on file)

  • Berry H, Bird HA, Black C, Blake DR, Freeman AM, Golding DN, Hamilton EB, Jayson MI, Kidd B, Kohn H, et al (1992) A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 51: 238–242

    Article  PubMed  CAS  Google Scholar 

  • Kidd B, Frenzel W (1996) A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 23: 1605–1611

    PubMed  CAS  Google Scholar 

  • Charlot J (1993) Study of long-term clinical tolerance and effects on laboratory parameters of Lornoxicam in elderly subjects suffering from osteoarthritis of the lower limbs or rheumatoid arthritis. Nycomed Pharma AG, Denmark (Data on file)

  • Nycomed_Pharma_AG Comparison of the efficacy and safety of lornoxicam and diclofenac in rheumatoid arthritis: a multicentre double-blind study followed by treatment with lornoxicam. Nycomed Pharma AG, Denmark (Data on file)

  • Caruso I, Montrone F, Boari L (1994) Lornoxicam versus diclofenac in rheumatoid arthritis: a double-blind, multi-center study. Adv Ther 11: 132–138

    Google Scholar 

  • Bernstein RM, Frenzel W (1995) A comparative study of two dosage regimens of lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. Eur J Clin Res 7: 259–273

    Google Scholar 

  • Leeb B Lornoxicam in the management of rheumatoid arthritis: a comparative study with piroxicam followed by long-term open-label treatment with lornoxicam. Nycomed Pharma AG, Denmark (Data on file)

  • Nycomed_Pharma_AG A multicentre study using a randomised, bi-phase (double-blind/open-labelled) parallel group design in patients suffering from acute sciatica (3n = 90 for the confirmatory analysis). Nycomed Pharma AG, Denmark (Data on file)

  • Augustin J, Adamczyk A (1995) Multiple-dose study comparing the efficacy and safety of lornoxicam with placebo and diclofenac in patients with acute sciatica or lumbo-sciatica. Nycomed Pharma AG, Denmark (Data on file)

  • Rainer F, Klein G, Mayrhofer F (1996) A prospective, multicentre, open-label, uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. Eur J Clin Res 8: 1–13

    Google Scholar 

  • Yakhno N, et al (2006) A randomised, double-blind, multi-centre clinical trial comparing efficacy and safety of the oral quick release formulation of Lornoxicam with Diclofenac Potassium in patients suffering from acute low back pain. Nycomed Pharma AG, Denmark Clin Drug Invest 26: 267–277

    Article  CAS  Google Scholar 

  • Bias P, Kursten F (1994) Analgesic therapy in chronic low back pain: comparative study of lornoxicam versus placebo and naproxen. Paper presented at: Schmerzkongreß, Dresden, Germany

  • Thienthong S, Jirarattanaphochai K, Krisanaprakornkit W, Simajareuk S, Tantanatewin W, Sathitkarnmanee A (2004) Treatment of pain after spinal surgery in the recovery room by single dose lornoxicam: a randomized, double blind, placebo-controlled trial. J Med Assoc Thai 87: 650–655

    PubMed  Google Scholar 

  • Staunstrup H, Ovesen J, Larsen UT, Elbaek K, Larsen U, Kroner K (1999) Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol 39: 834–841

    Article  PubMed  CAS  Google Scholar 

  • Rosenow DE, Albrechtsen M, Stolke D (1998) A comparison of patient-controlled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery. Anesth Analg 86: 1045–1050

    Article  PubMed  CAS  Google Scholar 

  • Ilias W, Jansen M (1996) Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Br J Clin Pract 50: 197–202

    PubMed  CAS  Google Scholar 

  • Trampitsch E, Pipam W, Moertl M, Sadjak A, Dorn C, Sittl R, Likar R (2003) Preemptive randomized, double-blind study with lornoxicam in gynecological surgery. Schmerz 17: 4–10

    Article  PubMed  CAS  Google Scholar 

  • Visalyaputra S, Sanansilp V, Pechpaisit N, Choavarartana R, Sritisarn S, Ungpinitpong W, Permpolprasert L, Apidechakul P (2002) Postoperative analgesic effects of intravenous lornoxicam and morphine with pre-emtive ropivacaine skin infiltration and preperitoneal instillation after transabdominal hysterectomy. J Med Assoc Thai 85 (Suppl 3): S1010–S1016

    PubMed  Google Scholar 

  • Hein A, Norlander C, Blom L, Jakobsson J (2001) Is pain prophylaxis in minor gynaecological surgery of clinical value? a double-blind placebo controlled study of paracetamol 1 g versus lornoxicam 8 mg given orally. Ambul Surg 9: 91–94

    Article  PubMed  Google Scholar 

  • Gong ZY, Ye TH, Qin XT, Yu GX, Guo XY, Luo AL (2001) Patient-controlled analgesia with lornoxicam in patients undergoing gynecological surgery. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 23: 472–475

    PubMed  CAS  Google Scholar 

  • Zhao H, Ye TH, Gong ZY, Xue Y, Xue ZG, Huang WQ (2005) Application of lornoxicam to patient-controlled analgesia in patients undergoing abdominal surgeries. Chin Med Sci J 20: 59–62

    PubMed  CAS  Google Scholar 

  • Ovechkin AM, Karpov IA, Liuosev SV (2003) [Postoperative analgesia in abdominal surgery: a new look at an old problem]. Anesteziol Reanimatol 45–50

  • Patel A, Skelly AM, Kohn H, Preiskel HW (1991) Double-blind placebo-controlled comparison of the analgesic effects of single doses of lornoxicam and aspirin in patients with postoperative dental pain. Br Dent J 170: 295–299

    PubMed  CAS  Google Scholar 

  • Norholt SE, Sindet-Pedersen S, Bugge C, Branebjerg PE, Ersboll BK, Bastian HL (1995) A randomized, doubleblind, placebo-controlled, dose-response study of the analgesic effect of lornoxicam after surgical removal of mandibular third molars. J Clin Pharmacol 35: 606–614

    PubMed  CAS  Google Scholar 

  • Norholt SE, Sindet-Pedersen S, Larsen U, Bang U, Ingerslev J, Nielsen O, Hansen HJ, Ersboll AK (1996) Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Pain 67: 335–343

    Article  PubMed  CAS  Google Scholar 

  • Norholt SE (1998) LO-025-DK. A comparative study of the analgesic efficacy of lornoxicam in the quick release tablet and the standard tablet formulations in patients with pain after third molar dental surgery. A single dose, randomised, double-blind, placebocontrolled, parallel group phase III study. Nycomed Pharma AG, Denmark (Data on file)

  • Malyshev VD, Zhdanov AM, Sviridov SV, Gukov AO, Termosesov SA, Vedenina IV, Nekrasova VS, Petukhova E, D'Iakov K A, Generozova VB, et al (2001) [Anesthesiology in the surgical treatment of supraventricular tachyarrhythmias]. Anesteziol Reanimatol 8–10

  • Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D (1999) The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res 48: 369–379

    Article  PubMed  CAS  Google Scholar 

  • Memis D, Karamanlioglu B, Turan A, Koyuncu O, Pamukcu Z (2004) Effects of lornoxicam on the physiology of severe sepsis. Crit Care 8: R474–R482

    Article  PubMed  Google Scholar 

  • Likar R, Kroner K, Narinder R, Homdrum E (2002) Lornoxicam: As safe as standard analgesics in postoperative pain in 3752 day case surgery patients. Nycomed Pharma AG, Denmark (Data on file)

  • Rothstein R (1998) Safety profiles of leading nonsteroidal anti-inflammatory drugs. Am J Med 105: 39S–43S

    Article  PubMed  CAS  Google Scholar 

  • Kehlet H, Dahl JB (1992) Are perioperative nonsteroidal anti-inflammatory drugs ulcerogenic in the short term? Drugs 44 (Suppl 5): 38–41

    PubMed  Google Scholar 

  • Warrington SJ, Debbas NM, Farthing M, Horton M, Johnston A, Thillainayagam A, Turner P, Ferber H (1990) Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men. Postgrad Med J 66: 622–626

    PubMed  CAS  Google Scholar 

  • Aabakken L, Osnes M, Frenzel W (1996) Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther 10: 151–156

    Article  PubMed  CAS  Google Scholar 

  • Dubois RW, Melmed GY, Henning JM, Laine L (2004) Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19: 197–208

    Article  PubMed  CAS  Google Scholar 

  • Ankier SI, Brimelow AE, Crome P, Johnston A, Warrington SJ, Turner P, Ferber HP (1988) Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J 64: 752–754

    PubMed  CAS  Google Scholar 

  • Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Adu D (1986) Non-steroidal anti-inflammatory drugs and renal failure. Lancet 1: 57–60

    Article  PubMed  CAS  Google Scholar 

  • Mather LE (1992) Do the pharmacodynamics of the non-steroidal anti-inflammatory drugs suggest a role in the management of postoperative pain? Drugs 44 (Suppl 5): 1–12; discussion 13

    Article  PubMed  Google Scholar 

  • Warrington SJ, Lewis Y, Dawnay A, Johnston A, Kovacs IB, Lamb E, Ravic M (1990) Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation. Postgrad Med J 66 (Suppl 4): S35–S40

    PubMed  CAS  Google Scholar 

  • Cunningham J (1993) An open study to determine the effect of renal insufficiency on the pharmacokinetics of Lornoxicam and to assess the tolerability of the drug in patients with renal insufficiency. Nycomed Pharma AG, Denmark (Data on file)

  • Haug-Pihale G, Geisler J (1993) Study for evaluation of the pharmacokinetics after multiple dose administration of lornoxicam 8 mg tablets in patients with impaired liver function compared to healthy controls. Clinical Study Report CT 73, Nycomed Pharma, Denmark (Data on file)

  • Blaicher AM, Landsteiner HT, Zwerina J, Leitgeb U, Volf I, Hoerauf K (2004) Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time. Anaesthesia 59: 1100–1103

    Article  PubMed  CAS  Google Scholar 

  • Blaicher AM, Landsteiner HT, Al-Falaki O, Zwerina J, Volf I, Gruber D, Zimpfer M, Hoerauf K (2004) Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression. Anesth Analg 98: 1082–1085

    Article  PubMed  CAS  Google Scholar 

  • Radhofer-Welte S, Rabasseda X (2000) Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc) 36: 55–76

    CAS  Google Scholar 

  • Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366

    Article  PubMed  CAS  Google Scholar 

  • Souter AJ, Fredman B, White PF (1994) Controversies in the perioperative use of nonsterodial antiinflammatory drugs. Anesth Analg 79: 1178–1190

    Article  PubMed  CAS  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899

    Article  PubMed  CAS  Google Scholar 

  • Garcia Rodriguez LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769–772

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nycomed Austria GmbH, Austria

    E.-M. Homdrum

  2. Pain Clinic, General Hospital, Klagenfurt, Austria

    R. Likar

  3. NPC Nell Pharma Connect GmbH., Austria

    G. Nell

Authors
  1. E.-M. Homdrum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Likar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Nell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E.-M. Homdrum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Homdrum, EM., Likar, R. & Nell, G. Xefo® Rapid: A novel effective tool for pain treatment. Eur Surg 38, 342–352 (2006). https://doi.org/10.1007/s10353-006-0272-6

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10353-006-0272-6

Schlüsselwörter

Keywords

Search

Navigation